The PRINCE (Proteomics-based Research Initiative for Non-CYP Enzymes) program is a research collaboration between the University of Washington and pharmaceutical industry to elucidate role of non-cytochrome P450 (non-CYP) enzymes in disposition, efficacy and toxicity of drugs.

We study drug-exposome-gene interactions in populations underrepresented in clinical trials by utilizing multi-omics and physiologically-based pharmacokinetics modeling approaches.

In my role as a Director of Industry Engagement of WSU CPPS, I am looking forward to interact with pharma and biotech industry to explore industry collaborations on areas of mutual interest, IP out-licensing/technology-transfers, and internships and job opportunities for our graduate and professional students. Through these mechanisms, we are hoping to develop a robust stream of next generation pharma/biotech scientists, practitioners and entrepreneurs at the CPPS.

The UWRAPT (University of Washington Research Affiliate program on Transporters) is a research collaboration between academia and pharmaceutical industry to better understand inter-individual variability in pharmacokinetics and pharmacodynamics of drugs. If you are interested in collaborating with UWRAPT, please visit our website or write an email.https://sop.washington.edu/department-of-pharmaceutics/research-affiliate-program-on-transporters-uwrapt/

Leading projects on quantitative proteomics and providing collaborative support to other researchers with respect to: 1) Targeted quantification of proteins in tissues and biofluids2) Targeted quantification of hypothesis driven posttranslational modifications3) Identification of site of covalent modification in proteins by xenobiotics

Drug metabolism and pharmacokinetics (preclinical)